Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study of Targeted Survivin DC Cell Injection for the Treatment of Newly Diagnosed Primary Glioblastoma Multiforme (GBM)

NCT06524063 is registered in ClinicalTrials.gov with Beijing Tricision Biotherapeutics Inc as lead sponsor.

NCT NCT06524063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06524063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study of Targeted Survivin DC Cell Injection for the Treatment of Newly Diagnosed Primary Glioblastoma Multiforme (GBM)
Lead sponsor
Beijing Tricision Biotherapeutics Inc
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2024
Completion date
October 1, 2027
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma